Clinical bottom line
Artificial intelligence (AI) applied to microbiome data holds emerging potential to predict pathological features relevant to disease diagnosis, prognosis, and personalized therapy. Machine learning models leveraging large-scale microbiome datasets can identify microbial signatures associated with disease states and predict clinical outcomes with increasing accuracy. However, current evidence remains largely exploratory, with challenges including data heterogeneity, interpretability, and validation across populations. While promising for precision pathology, AI-driven microbiome analysis requires further rigorous validation before routine clinical implementation (Turroni et al., 2024; Chaves Cano et al., 2026).
What the evidence shows
Turroni et al. (2024) review the application of machine learning to microbiome big data, highlighting its capacity to integrate complex microbial community profiles with clinical metadata to predict disease outcomes. They describe models that classify disease phenotypes such as inflammatory bowel disease and colorectal cancer based on microbial composition, achieving moderate to high predictive performance.
Chaves Cano et al. (2026) focus on AI in oral microbiome and dental genomics, demonstrating that AI algorithms can identify microbial patterns linked to periodontal disease and caries risk. Their evidence matrix review underscores the utility of AI for biomarker discovery and risk stratification in oral pathology.
Liu et al. (2026) illustrate advanced multimodal AI approaches combining microbiome features with protein post-translational modification data to enhance prediction of pathological states, suggesting integrative models may improve accuracy.
While these studies demonstrate proof-of-concept, Gupta et al. (2024) and Eklou et al. (2024) provide broader context on AI’s predictive capabilities in complex biological systems, emphasizing the importance of robust training data and validation.
Caveats and uncertainty
Most studies are retrospective, with limited prospective validation in independent cohorts.
Variability in sample collection, sequencing methods, and bioinformatics pipelines complicates reproducibility.
AI models often lack transparency, limiting interpretability and clinical trust.
Population diversity and environmental factors influencing the microbiome are underrepresented in many datasets.
Clinical utility, cost-effectiveness, and integration into pathology workflows remain unproven.
How this may change practice
AI-enhanced microbiome analysis could augment pathological assessment by providing non-invasive biomarkers predictive of disease progression or therapeutic response.
Integration of microbiome-derived predictions with histopathology and molecular diagnostics may enable more precise disease classification.
Pathologists may increasingly collaborate with bioinformaticians and data scientists to interpret AI outputs.
Future clinical workflows might incorporate AI tools for early detection, risk stratification, and monitoring of microbiome-associated diseases.
Ongoing validation and standardization efforts are essential before widespread clinical adoption.